The Warsaw, Poland-based firm will also use some of the funding to commercialize a phenotypic antibiotic susceptibility testing system.
Inspirata said that the partners will combine their digital pathology products to address challenges with traditional pathology testing for H. Pylori.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The firm said that its panel enables receipt of results for life-threatening conditions, such as sepsis and bacteremia, within about 11 minutes at the point of care.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
Specific Diagnostics said it plans to apply CE marking to the Reveal system next year, followed by submission to the FDA for 510(k) clearance.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
Specific Diagnostics said that the CARB-X funding will enable it to prepare its AST instrument for clinical trials and regulatory validation.